WESTBURY, N.Y., Sept. 13, 2011 /PRNewswire/ -- We are pleased to announce that Paul F. Vogel has been appointed Chief Executive Officer (CEO) of Lachman Consultant Services, Inc. Paul brings 40 years of experience to this position. He has served Lachman Consultants for many years as Executive Vice President/Compliance and as a member of its Board of Directors. Before consulting, Paul served the US FDA for 21 years in key executive management positions, including Acting Director - Office of Compliance/CDER, Director - Division of Manufacturing Practice and Product Quality/CDER, Director - Division of Drug Quality Evaluation/CDER, and Director - Government-Wide Quality Assurance Program for Drug, Biologic and In Vitro Diagnostic products. In his new position, Paul will be working with Chairman Leon Lachman, Ph.D. with the strategic direction and oversight of the company, and with President Roy Sturgeon, Ph.D. to advise and support the management of the company's diverse operations. Paul looks forward to continuing to work closely with Lachman Consultants' clientele, FDA and other regulatory authorities to strengthen and maintain GXP-wide industry programs and to prevent or resolve complex regulatory and compliance problems.
For more than 30 years, Lachman Consultants has been the leader in providing cost-effective consultation and remediation services to the worldwide pharmaceutical, biotechnology, biologic, medical device, diagnostic and dietary supplement industries. With its strong and extensive cadre of consultant specialists and an unparalleled management team, its Compliance, Science & Technology, and Regulatory Practices provide the most expert counsel and array of services available. Lachman Consultants is proud of its tradition of supporting industry efforts to develop and ensure safe, effective and high-quality medical products. It remains committed to helping the industry anticipate and address its challenges through the development and implementation of practical, sustainable and cost-effective solutions based on the integration of scientific principles, evolving regulatory expectations, and technology.
CONTACT: Michele Sinoway, (516) 222-6222, [email protected]
SOURCE Lachman Consultant Services, Inc.